Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Lübbert

Showing results (11-20 of 247) with videos related to

Pageof 25
Sort By:
Seminars in Hematology|March 31, 2019
Can we predict responsiveness to hypomethylating agents in AML?Julia Stomper, Michael Lübbert
Annals of Hematology|November 26, 2005
The hematopathological basis for studying effects of the demethylating agent 5-aza-2'-deoxycytidine (decitabine) in myelodysplasiaHans Eckart Schaefer, Michael Lübbert
Seminars in Hematology|October 20, 2012
Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an updateTina E Joeckel, Michael Lübbert
Cancer Cell|March 28, 2025
All-trans retinoic acid beyond acute promyelocytic leukemiaUsama-Ur Rehman, Michael Lübbert
Seminars in Oncology|October 8, 2005
Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agentsRainer Claus, Maika Almstedt, Michael Lübbert
Leukemia Research|July 31, 2017
Immunotherapy in adult acute leukemiaSabine Blum, Filipe Martins, Michael Lübbert
Journal of Cancer Research and Clinical Oncology|August 30, 2002
p53 Germline mutation in a patient with Li-Fraumeni Syndrome and three metachronous malignanciesClaudia Pötzsch, Theda Voigtländer, Michael Lübbert
Stem Cells (Dayton, Ohio)|January 17, 2003
CD34- hematopoietic stem cells: current concepts and controversiesYalin Guo, Michael Lübbert, Monika Engelhardt
European Journal of Haematology|August 18, 2009
Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML)Björn Hackanson, Anja Rückert, Michael Lübbert
Annals of Hematology|August 17, 2013
No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year "real-life" evaluationHartmut Bertz, Kathrin Drognitz, Michael Lübbert
Pageof 25

Showing results (11-20 of 247) with videos related to

Sort By:
Pageof 25
Seminars in Hematology|March 31, 2019
Can we predict responsiveness to hypomethylating agents in AML?Julia Stomper, Michael Lübbert
Annals of Hematology|November 26, 2005
The hematopathological basis for studying effects of the demethylating agent 5-aza-2'-deoxycytidine (decitabine) in myelodysplasiaHans Eckart Schaefer, Michael Lübbert
Seminars in Hematology|October 20, 2012
Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an updateTina E Joeckel, Michael Lübbert
Cancer Cell|March 28, 2025
All-trans retinoic acid beyond acute promyelocytic leukemiaUsama-Ur Rehman, Michael Lübbert
Seminars in Oncology|October 8, 2005
Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agentsRainer Claus, Maika Almstedt, Michael Lübbert
Leukemia Research|July 31, 2017
Immunotherapy in adult acute leukemiaSabine Blum, Filipe Martins, Michael Lübbert
Journal of Cancer Research and Clinical Oncology|August 30, 2002
p53 Germline mutation in a patient with Li-Fraumeni Syndrome and three metachronous malignanciesClaudia Pötzsch, Theda Voigtländer, Michael Lübbert
Stem Cells (Dayton, Ohio)|January 17, 2003
CD34- hematopoietic stem cells: current concepts and controversiesYalin Guo, Michael Lübbert, Monika Engelhardt
European Journal of Haematology|August 18, 2009
Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML)Björn Hackanson, Anja Rückert, Michael Lübbert
Annals of Hematology|August 17, 2013
No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year "real-life" evaluationHartmut Bertz, Kathrin Drognitz, Michael Lübbert
Pageof 25